JERSEY, Channel Islands, Feb. 06, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported further positive progress on the commercial scale-up of MosaiQ™ and its financial results for its fiscal third quarter and nine months ended December 31, 2016.
“Our team continues to work diligently to advance MosaiQ™ through to the final internal validation process prior to commencing European field trials,” said Paul Cowan, Chairman and Chief Executive Officer of Quotient. “Final internal performance evaluation studies for the initial disease screening panel have now been completed successfully. We remain on schedule to complete European field trials for MosaiQ™ for blood grouping and the initial disease screening panel in the first half of calendar 2017.”
